Race Oncology Limited operates as a specialty pharmaceutical company in Australia.
+ 1 more risk
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Race Oncology's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: RAC's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: RAC exceeded the Australian Biotechs industry which returned 25.1% over the past year.
Return vs Market: RAC exceeded the Australian Market which returned -7.8% over the past year.
Price Volatility Vs. Market
How volatile is Race Oncology's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StCan You Imagine How Elated Race Oncology's (ASX:RAC) Shareholders Feel About Its 442% Share Price Gain?
3 months ago | Simply Wall StDo Directors Own Race Oncology Limited (ASX:RAC) Shares?
3 months ago | Simply Wall StIs Race Oncology Limited's (ASX:RAC) CEO Paid Enough Relative To Peers?
Is Race Oncology undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate RAC's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate RAC's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: RAC is unprofitable, so we can't compare its PE Ratio to the XX Biotechs industry average.
PE vs Market: RAC is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RAC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RAC is overvalued based on its PB Ratio (17.8x) compared to the AU Biotechs industry average (3.6x).
How is Race Oncology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Race Oncology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Race Oncology's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Race Oncology competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Race Oncology performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RAC is currently unprofitable.
Growing Profit Margin: RAC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: RAC is unprofitable, and losses have increased over the past 5 years at a rate of 35.7% per year.
Accelerating Growth: Unable to compare RAC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RAC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-5.6%).
Return on Equity
High ROE: RAC has a negative Return on Equity (-57.41%), as it is currently unprofitable.
How is Race Oncology's financial position?
Financial Position Analysis
Short Term Liabilities: RAC's short term assets (A$1.6M) exceed its short term liabilities (A$221.3K).
Long Term Liabilities: RAC has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: RAC is debt free.
Reducing Debt: RAC had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RAC has sufficient cash runway for 10 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: RAC is forecast to have sufficient cash runway for 8 months based on free cash flow estimates, but has since raised additional capital.
What is Race Oncology current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RAC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RAC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RAC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RAC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RAC's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Race Oncology has no CEO, or we have no data on them.
|Executive Chairman||0.42yr||AU$129.53k||3.09% |
|COO & Non-Executive Director||0.92yr||no data||7.49% |
|Non Executive Director||4.08yrs||AU$121.00k||11.35% |
|Non-Executive Director||4.33yrs||AU$48.00k||0.85% |
|Member of Scientific Advisory Board||3.67yrs||no data||no data|
|Independent Non-Executive Director||0.17yr||no data||0.34% |
|Member of Scientific Advisory Board||no data||no data||no data|
|Member of Scientific Advisory Board||no data||no data||no data|
|Chairman of Clinical Advisory Board & Non-Executive Director||0.83yr||no data||no data|
|Member of Clinical Advisory Board||0.50yr||no data||no data|
Experienced Board: RAC's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: RAC insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 40.7%.
Race Oncology Limited's company bio, employee growth, exchange listings and data sources
- Name: Race Oncology Limited
- Ticker: RAC
- Exchange: ASX
- Founded: 2011
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$108.650m
- Shares outstanding: 122.77m
- Website: https://www.raceoncology.com
- Race Oncology Limited
- 140 William Street
- Level 40
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|RAC||CHIA (Chi-X Australia)||Yes||Common Shares||AU||AUD||Jul 2016|
|RAC||ASX (Australian Securities Exchange)||Yes||Common Shares||AU||AUD||Jul 2016|
Race Oncology Limited operates as a specialty pharmaceutical company in Australia. It is developing Bisantrene, a small molecule cancer chemotherapy drug that is used for the treatment of acute myeloid leu ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/08/07 10:32|
|End of Day Share Price||2020/08/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.